title: Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.
abstract: The current third consensus on the systemic treatment of non-small-cell lung cancer (NSCLC) builds upon and updates similar publications on the subject by the Central European Cooperative Oncology Group (CECOG), which has published such consensus statements in the years 2002 and 2005 (Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer--update 2004. Lung Cancer 2005; 50: 129-137). The principle of all CECOG consensus is such that evidence-based recommendations for state-of-the-art treatment are given upon which all participants and authors of the manuscript have to agree (Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771-1785). This is of particular importance in diseases in which treatment options depend on very particular clinical and biologic variables (Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer--update 2004. Lung Cancer 2005; 50: 129-137; Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771-1785). Since the publication of the last CECOG consensus on the medical treatment of NSCLC, a series of diagnostic tools for the characterization of biomarkers for personalized therapy for NSCLC as well as therapeutic options including adjuvant treatment, targeted therapy, and maintenance treatment have emerged and strongly influenced the field. Thus, the present third consensus was generated that not only readdresses previous disease-related issues but also expands toward recent developments in the management of NSCLC. It is the aim of the present consensus to summarize minimal quality-oriented requirements for individual patients with NSCLC in its various stages based upon levels of evidence in the light of a rapidly expanding array of individual therapeutic options.
authors.affiliation: Clinical Division of Oncology, Comprehensive Cancer Center, Medical University Vienna-General Hospital, Vienna, Austria; Central European Cooperative Oncology Group.
authors.forename: T
authors.initials: T
authors.lastname: Brodowicz
authors.affiliation: Medical Oncology Department, Institute of Oncology, Cluj-Napoca, Romania.
authors.forename: T
authors.initials: T
authors.lastname: Ciuleanu
authors.affiliation: Department of Medicine, Duke Medical Center, Durham, USA.
authors.forename: J
authors.initials: J
authors.lastname: Crawford
authors.affiliation: Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University Vienna-General Hospital, Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Filipits
authors.affiliation: Department of Medicine II, Onkology, Klinik Löwenstein, Löwenstein, Germany.
authors.forename: J R
authors.initials: JR
authors.lastname: Fischer
authors.affiliation: Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece.
authors.forename: V
authors.initials: V
authors.lastname: Georgoulias
authors.affiliation: Division of Medical Oncology, S.G. Moscati Hospital, Contrada Amoretta, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Gridelli
authors.affiliation: Department of Pathology, University of Colorado, Aurora, USA.
authors.forename: F R
authors.initials: FR
authors.lastname: Hirsch
authors.affiliation: Central European Cooperative Oncology Group; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Jassem
authors.affiliation: Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
authors.forename: P
authors.initials: P
authors.lastname: Kosmidis
authors.affiliation: Central European Cooperative Oncology Group; Department of Lung and Thoracic Tumours, Maria Sklodowska Curie Memorial Cancer Center, Warsaw, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Krzakowski
authors.affiliation: Department of Surgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
authors.forename: Ch
authors.initials: C
authors.lastname: Manegold
authors.affiliation: Department of Oncology Lung, Hopital Arnaud de Villeneuve, Montpellier, France.
authors.forename: J L
authors.initials: JL
authors.lastname: Pujol
authors.affiliation: Laboratory for Molecular Oncology, Department of Thoracic Oncology, Clinic and Policlinic for Oncology, University Hospital Zurich, Zurich, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Stahel
authors.affiliation: Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.
authors.forename: N
authors.initials: N
authors.lastname: Thatcher
authors.affiliation: Respiratory Oncology Unit (Pulmonology), University Hospital Gasthuisberg, Leuven, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Vansteenkiste
authors.affiliation: Clinical Division of Oncology, Comprehensive Cancer Center, Medical University Vienna-General Hospital, Vienna, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Minichsdorfer
authors.affiliation: Clinical Division of Oncology, Comprehensive Cancer Center, Medical University Vienna-General Hospital, Vienna, Austria.
authors.forename: S
authors.initials: S
authors.lastname: Zöchbauer-Müller
authors.affiliation: Clinical Division of Oncology, Comprehensive Cancer Center, Medical University Vienna-General Hospital, Vienna, Austria.
authors.forename: R
authors.initials: R
authors.lastname: Pirker
authors.affiliation: Clinical Division of Oncology, Comprehensive Cancer Center, Medical University Vienna-General Hospital, Vienna, Austria; Central European Cooperative Oncology Group. Electronic address: christoph.zielinski@meduniwien.ac.at.
authors.forename: C C
authors.initials: CC
authors.lastname: Zielinski
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000601:surgery*; D008495:Medical Oncology / Q000331:legislation & jurisprudence / Q000458:organization & administration / Q000639:trends; D020360:Neoadjuvant Therapy; D012196:Review Literature as Topic; D012955:Societies, Medical / Q000331:legislation & jurisprudence